Menu
Recruiting NCT07311434

Sleep and Morning Wellbeing Study

No phase Interventional Sleep Relaxation Stress Daytime Sleepiness

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Sleep Supplement.
Who it may be relevant to
Registry conditions: Sleep, Relaxation, Stress, Daytime Sleepiness. Basic parameters: 22 years — 59 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Evaluation of Perceived Outcomes With AGZ: A Randomized, Controlled, Consumer Perception Study

Overview

The study will be a prospective randomized, controlled clinical study. There will be interventional treatment for a total of 30 days. The subjects will complete questionnaires throughout the study at pre-specified timepoints.

Interventions

  • Dietary supplement Sleep Supplement
    Powdered sleep supplement

Primary outcome measures

  • Evening relaxation, sleep quality, and morning vitality [Time frame: Days 1, 3, 7, 14, 30]

Eligibility criteria

Inclusion criteria

  • Male or female.
  • Age 25-59 years.
  • BMI ≥18.5 and ≤29.9 kg/m².
  • Currently experiencing issues with sleep quality, falling asleep, staying asleep, or waking during the night.
  • RU-SATED score ≤17.
  • Willing and able to follow the study protocol.
  • Willing to discontinue any other supplements (including nootropics, adaptogens, calming herbs), medications, herbal remedies, or over-the-counter sleep medications (e.g., zolpidem, diphenhydramine, Benadryl, ZzzQuil, Unisom, magnesium or melatonin products) used to assist with sleep during the study.
  • Agree to limit alcohol intake within approximately 4 hours of bedtime throughout participation.
  • Agree to limit caffeine intake to ≤400 mg/day (about 3-4 cups of coffee) and avoid ingestion of caffeine-containing products after 2:00 PM during the study period.
  • Generally healthy and not living with any uncontrolled chronic disease.
  • Resides in the United States.
  • Willing to discontinue any restricted products and adhere to all required study assessments.

Exclusion criteria

  • Diagnosed chronic sleep conditions (e.g., insomnia, narcolepsy, REM Behavior Disorder, moderate to severe restless leg syndrome, sleep apnea).
  • Current use of sleep-tracking technology (e.g., wrist-worn trackers, rings, smartphone apps) that could influence sleep behavior or perception.

Women currently undergoing perimenopause or experiencing vasomotor symptoms (e.g., night sweats).

  • Use of hormone therapy (estrogen, progesterone, phytoestrogens) within the last 3 months.
  • Diagnosed psychiatric disorders including major depressive disorder with acute symptoms, bipolar disorder, generalized anxiety disorder with active symptoms, and PTSD with frequent nightmares.
  • Diagnosed neurodegenerative or chronic pain disorders, including Parkinson's disease, Alzheimer's disease, or uncontrolled fibromyalgia.
  • Regular prescribed stimulant use (e.g., amphetamines such as Adderall/Vyvanse; methylphenidate such as Ritalin/Concerta; modafinil/armodafinil).
  • Current use of CNS-activating antidepressants (bupropion, fluoxetine, venlafaxine, sertraline).
  • Current or recent use of cannabis or THC-containing products (recreational or medicinal marijuana, CBD with measurable THC, synthetic cannabinoids) within the past 30 days.
  • Employment in jobs disrupting nighttime sleep (e.g., night shift, rotating shift, excessive travel).
  • Current use of prescription sleep aids.
  • Introduction of any new sleep-related supplements, medications, herbal remedies, or melatonin products during the study.
  • Use of any prescription or OTC products with sedative properties (e.g., melatonin, diphenhydramine, doxylamine, valerian, ZzzQuil, Advil PM) within 4 weeks prior to enrollment or habitual use ≥3 times per week prior to enrollment unless investigator-approved.
  • Allergy or sensitivity to any study product ingredients.
  • Pregnant, breastfeeding, or trying to conceive during the study period.
  • History of substance abuse.
  • Heavy alcohol use (≥8 drinks/week for women or ≥15 drinks/week for men).
  • Participation in another research study now or within the next 7 weeks.
  • Any condition or behavior that, in the investigator's judgment, may interfere with study participation or data integrity.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Other

Study locations

United States · 1 center
  • Alethios (Virtual Study Platform) — San Francisco

Identifiers

NCT: NCT07311434 · AGZ001

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗